Literature DB >> 6347372

Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells.

H F Dvorak, L Van DeWater, A M Bitzer, A M Dvorak, D Anderson, V S Harvey, R Bach, G L Davis, W DeWolf, A C Carvalho.   

Abstract

Thirteen of 14 tumor cells or tumor cell lines of guinea pig, mouse, and human origin spontaneously shed procoagulant activity in short-term (4 or 14 to 22 hr) tissue culture under conditions of high cell viability. This released procoagulant activity was pelletable in the ultracentrifuge and was associated with plasma membrane-derived vesicles as determined by transmission electron microscopy and marker enzyme analysis. The procoagulant activity shed corresponded to a substantial fraction of that expressed by intact or sonicated tumor cells and was composed of activities interacting at more than a single step in the clotting sequence. One procoagulant activity associated with shed human tumor vesicles behaved as tissue factor, requiring Factor VII for activity and being inhibited by a specific anti-bovine tissue factor antibody. Guinea pig tumor vesicles also exhibited tissue factor-like activity in a two-stage assay using homologous first-stage Factor VII/X concentrate. None of the human vesicles tested expressed a direct Factor X cleaving activity, independent of Factor VII. Shed tumor vesicles also acted at a second step late in the clotting cascade at the level of prothrombinase generation, presumably by providing a phospholipid surface. Taken together, these data indicate that a wide variety of tumor cells release plasma membrane vesicles with procoagulant activity. Such vesicles, as well as intact tumor cells themselves, may play an important role in the biology of tumor growth by inducing the local fibrin deposits found in association with many solid tumors.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6347372

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis.

Authors:  Katrin F Nickel; Göran Ronquist; Florian Langer; Linda Labberton; Tobias A Fuchs; Carsten Bokemeyer; Guido Sauter; Markus Graefen; Nigel Mackman; Evi X Stavrou; Gunnar Ronquist; Thomas Renné
Journal:  Blood       Date:  2015-07-07       Impact factor: 22.113

Review 2.  Tumors: wounds that do not heal-redux.

Authors:  Harold F Dvorak
Journal:  Cancer Immunol Res       Date:  2015-01       Impact factor: 11.151

Review 3.  Microvesicles: mediators of extracellular communication during cancer progression.

Authors:  Vandhana Muralidharan-Chari; James W Clancy; Alanna Sedgwick; Crislyn D'Souza-Schorey
Journal:  J Cell Sci       Date:  2010-05-15       Impact factor: 5.285

Review 4.  Microparticles in hemostasis and thrombosis.

Authors:  A Phillip Owens; Nigel Mackman
Journal:  Circ Res       Date:  2011-05-13       Impact factor: 17.367

Review 5.  Mechanisms and biomarkers of cancer-associated thrombosis.

Authors:  Ann S Kim; Alok A Khorana; Keith R McCrae
Journal:  Transl Res       Date:  2020-07-06       Impact factor: 7.012

Review 6.  Studies on rat mammary adenocarcinomas: a model for metastasis.

Authors:  I A Ramshaw; P Badenoch-Jones
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

7.  Identification of an endothelial cell product as an inhibitor of tissue factor activity.

Authors:  P Colburn; V Buonassisi
Journal:  In Vitro Cell Dev Biol       Date:  1988-11

8.  Rat prostate tumors express cancer procoagulant, an activator of coagulation factor X.

Authors:  Malgorzata Kamocka; Morris Pollard; Mark Suckow; Wojciech P Mielicki; Elliot D Rosen
Journal:  Comp Med       Date:  2008-06       Impact factor: 0.982

9.  Tumors, ticks and tissue factor.

Authors:  T McEachron; N Mackman
Journal:  J Thromb Haemost       Date:  2009-08-19       Impact factor: 5.824

10.  Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients.

Authors:  M Mego; U De Giorgi; K Broglio; S Dawood; V Valero; E Andreopoulou; B Handy; J M Reuben; M Cristofanilli
Journal:  Br J Cancer       Date:  2009-11-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.